Navigation Links
Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
Date:11/19/2007

Commences Phase I Clinical Trial of Proprietary siRNA Molecule in Acute

Renal Failure

FREMONT, Calif., Nov. 19 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company focused on discovering and developing novel RNA interference-based therapeutics, announced today that it has commenced systemic dosing in humans of its proprietary product candidate, AKIi-5, a siRNA compound discovered and developed by Quark for the treatment of Acute Renal Failure (ARF), also called Acute Kidney Injury (AKI). Based on publicly available information, Quark believes that this is the first human clinical trial involving the systemic delivery of siRNA.

The Phase I clinical trial is a multi-center, double-blind, placebo controlled, dose-escalation trial assessing the safety and pharmacokinetics of AKIi-5 administered intravenously as a single dose to patients undergoing major cardiac surgery. Patients will be enrolled in the trial in a number of centers in the United States, Europe and Israel. Quark expects to complete the trial in early 2008. Depending on the results of this trial, Quark expects to initiate a dose-ranging Phase II clinical trial measuring AKIi-5 clinical activity.

Daniel Zurr, Chief Executive Officer, commented, "The initiation of human dosing in our Phase I trial in ARF signifies a very important step in Quark's clinical program and marks an important milestone in the RNAi industry. For Quark, the trial serves to further validate the strength of our pipeline and our overall expertise in the RNAi arena. With AKIi-5 now in the clinic, RTP801i-14, which we licensed to Pfizer, in a Phase I/IIa clinical trial for the treatment of wet age-related macular degeneration, AHLi-11 in IND-enabling studies and additional RNAi-based candidate drugs in pre-clinical testing, we believe Quark has one of the most robust RNAi product portfolios in the industry.

"For the RNAi industry, the trial m
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
3. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
4. Quark Pharmaceuticals Appoints New Chief Medical Officer
5. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
9. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
10. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
11. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... July 31, 2014 STAAR Surgical Company (NASDAQ: ... marketer of implantable lenses and delivery systems for the ... July 4, 2014 of $20.0 million, a 10% increase ... 2013. On a constant currency basis, revenues grew 11% ... second quarter of 2013.  The effect of foreign currency ...
(Date:7/31/2014)... 2014 IRIDEX Corporation (Nasdaq: IRIX ) ... months ended June 28, 2014.  , Revenues were ... from $9.2 million in the 2013 second quarter and up ... Revenues for the first six months of 2014 were $20.9 ... months of last year. , Gross margin for the ...
(Date:7/31/2014)... RMD ) today announced results for its fourth ... Revenue for the quarter was $415.2 million, flat compared to ... on a constant currency basis). Net income was $87.7 million, ... June 30, 2013. Diluted earnings per share for the quarter ... quarter ended June 30, 2013.  The results ...
Breaking Medicine Technology:STAAR Surgical Reports 10% Second Quarter Revenue Growth 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 4STAAR Surgical Reports 10% Second Quarter Revenue Growth 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 6STAAR Surgical Reports 10% Second Quarter Revenue Growth 7STAAR Surgical Reports 10% Second Quarter Revenue Growth 8STAAR Surgical Reports 10% Second Quarter Revenue Growth 9STAAR Surgical Reports 10% Second Quarter Revenue Growth 10STAAR Surgical Reports 10% Second Quarter Revenue Growth 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 12STAAR Surgical Reports 10% Second Quarter Revenue Growth 13STAAR Surgical Reports 10% Second Quarter Revenue Growth 14STAAR Surgical Reports 10% Second Quarter Revenue Growth 15STAAR Surgical Reports 10% Second Quarter Revenue Growth 16STAAR Surgical Reports 10% Second Quarter Revenue Growth 17STAAR Surgical Reports 10% Second Quarter Revenue Growth 18STAAR Surgical Reports 10% Second Quarter Revenue Growth 19STAAR Surgical Reports 10% Second Quarter Revenue Growth 20STAAR Surgical Reports 10% Second Quarter Revenue Growth 21STAAR Surgical Reports 10% Second Quarter Revenue Growth 22STAAR Surgical Reports 10% Second Quarter Revenue Growth 23STAAR Surgical Reports 10% Second Quarter Revenue Growth 24STAAR Surgical Reports 10% Second Quarter Revenue Growth 25STAAR Surgical Reports 10% Second Quarter Revenue Growth 26STAAR Surgical Reports 10% Second Quarter Revenue Growth 27STAAR Surgical Reports 10% Second Quarter Revenue Growth 28STAAR Surgical Reports 10% Second Quarter Revenue Growth 29STAAR Surgical Reports 10% Second Quarter Revenue Growth 30STAAR Surgical Reports 10% Second Quarter Revenue Growth 31IRIDEX Reports 2014 Second Quarter, Six-Month Results 2IRIDEX Reports 2014 Second Quarter, Six-Month Results 3IRIDEX Reports 2014 Second Quarter, Six-Month Results 4IRIDEX Reports 2014 Second Quarter, Six-Month Results 5IRIDEX Reports 2014 Second Quarter, Six-Month Results 6
... 10 Xanodyne Pharmaceuticals, Inc., an integrated specialty pharmaceutical company, ... the company on the pain management market.  The company plans to ... a range of products that address both the acute and chronic ... , , , ...
... Inc. (Nasdaq: YDNT ) today announced that its Board of Directors declared a ... to all shareholders of record on May 22, 2010 . , ... The Company also announced that its Board of Directors elected ... 2003 . He has assumed positions of increasing responsibility in the areas of finance, ...
Cached Medicine Technology:Xanodyne Announces Renewed Focus on Pain Management Market 2Xanodyne Announces Renewed Focus on Pain Management Market 3Xanodyne Announces Renewed Focus on Pain Management Market 4Young Innovations, Inc. Board of Directors Declares Quarterly Dividend and Announces Election of New Officer 2
(Date:7/31/2014)... (PRWEB) July 31, 2014 Insight Accelerator ... a Series A round of investment for $4.6 million ... device for collecting vital signs. The company joined ... technology to fruition with the help of Insight development ... our reason for launching the Accelerator,” says Steve McPhilliamy, ...
(Date:7/31/2014)... FL (PRWEB) July 31, 2014 Women ... to take charge of their financial future. The ... women, has opened registration for 6 upcoming Los Angeles ... women, for women, and with input from Kim Kiyosaki, ... and It’s Rising Time) who is passionate about women’s ...
(Date:7/31/2014)... New York (PRWEB) July 31, 2014 ... Ethicon, Inc. continue to move forward in the federal ... of West Virginia, Bernstein Liebhard LLP reports. According to ... scheduled to consider certain defense motions now pending before ... the U.S. Magistrate Judge on Tuesday, August 5th at ...
(Date:7/31/2014)... New York (PRWEB) July 31, 2014 ... grow, as Bernstein Liebhard LLP notes that Johnson ... it plans to voluntarily remove its power morcellators ... a report from Bloomberg.com, the company said it ... benefits associated with the devices remain uncertain.* , ...
(Date:7/31/2014)... Ticket Down is a reliable ... Sporting Goods Park in suburban Denver on Tuesday, September ... team has found a second home competing on American soil. ... playing international friendly games and will look to have another ... Park in Commerce City, Colorado. The match will be Mexico’s ...
Breaking Medicine News(10 mins):Health News:Insight Accelerator Labs Advances Member Toward Commercialization 2Health News:Insight Accelerator Labs Advances Member Toward Commercialization 3Health News:The Independent Woman to Offer Financial Workshops in the Los Angeles Area - Developed by Women for Women 2Health News:Ethicon Transvaginal Mesh Lawsuits Move Forward, With Scheduling of Hearing in Federal Litigation, Bernstein Liebhard LLP Reports 2Health News:Ethicon Transvaginal Mesh Lawsuits Move Forward, With Scheduling of Hearing in Federal Litigation, Bernstein Liebhard LLP Reports 3Health News:Uterine Morcellation Controversy Grows, as Bernstein Liebhard LLP Notes Johnson & Johnson Decision to Withdraw Power Morcellators from Market 2Health News:Uterine Morcellation Controversy Grows, as Bernstein Liebhard LLP Notes Johnson & Johnson Decision to Withdraw Power Morcellators from Market 3Health News:Mexico vs. Bolivia Tickets at Dick’s Sporting Goods Park in Commerce City (Denver), CO Now Available at Ticket Down 2Health News:Mexico vs. Bolivia Tickets at Dick’s Sporting Goods Park in Commerce City (Denver), CO Now Available at Ticket Down 3
... New food safety laws are to be introduced in Hong ... China, officials announced Thursday.// ,The measures will allow the ... sale if there are concerns, the territory's minister for health ... over fish and eggs imported into Hong Kong from China ...
... average around ?106,000 in the initial one year following ... and social care depict an increase in the average ... ,Ministers and NHS Bigwigs are mighty unhappy that huge ... them for improving the quality of healthcare services. However, ...
... that one in three cases of mentally ill patients ... after studying the statistics relating to hospitalization and patient ... those mentally ill patients readmitted, 45 percent of patients ... cent of people with schizophrenia and one in five ...
... of Medical Research, the data from Population Based Cancer ... the age specific// incidence rates of breast cancer below ... scheme of National Cancer Control Programme (NCCP), special emphasis ... by creating awareness. Grant-in-aid is provided to Non-Governmental Organisations ...
... in treatment of cancer, are likely to harm normal ... the Journal of Biology.// ,The study observed that ... be long lasting. This study gives a clue to ... that are seen in lots of cancer patients. Cancer ...
... Texas surgeons lead robotically assisted laparoscopic surgeries. A ... places in the body. Laparoscopic surgeons at// UT ... gastric-bypass and colon-resections surgeries. , Laparoscopic ... than one long incision. This usually results in ...
Cached Medicine News:Health News:Hong Kong to Tighten Food Safety Laws 2Health News:Mentally-Ill Patients Get Re-Hospitalized More 2Health News:North Texas Surgeons Lead Robotically Assisted Laparoscopic Surgeries. 2
... Tegagel hydrogel wound filler and Tegagel ... amorphous hydrogel dressings specially formulated to ... has been shown to enhance wound ... meets clinical needs for management of ...
... and Tegagel hydrogel wound filler with ... formulated to help provide a moist ... enhance wound healing. The unique, viscous, ... management of non-draining, minimally draining and ...
... a complete physician preference card system as ... for all the supply management requirements of ... system combined with a broad array of ... cart and operating suite supply and charge ...
... Esteem™ External Vacuum Therapy System restores sexual ... men. Non-invasive and low cost vacuum therapy, ... desirable outcome", makes it the ideal therapy ... Therapy System causes penile rigidity that can ...
Medicine Products: